Scientific Writing and Presentation Examples

Research Manuscript Examples

Authorship, Coordination, and Writing

Patient Challenges in Utilization of Methadone to Treat Opioid Use Disorder and Perspectives on a Solution for Improved Security and Convenience in Take-home Dosing. Morse E, Christianson G, Olivadoti M, Timberlake J. Innov Clin Neurosci. 2024 Dec 1;21(10):25-33. PMID: 39790898; PMCID: PMC11709438.

Pooled Results of Two Randomized Phase III Trials Evaluating VP-102, a Drug-Device Combination Product Containing Cantharidin 0.7% (w/v) for the Treatment of Molluscum Contagiosum. Eichenfield LF, Siegfried E, Kwong P, McBride M, Rieger J, Glover D, Willson C, Davidson M, Burnett P, Olivadoti M. Am J Clin Dermatol. 2021 Mar;22(2):257-265. doi: 10.1007/s40257-020-00570-8. Epub 2021 Feb 18.

COVE-1: A Phase 2, Open-Label Study to Evaluate Efficacy and Safety and the Optimal Regimen of VP-102, a Proprietary Drug-Device Product Containing Topical Cantharidin (0.7% w/v) Under Occlusion for the Treatment of Common Warts. Guenthner S, McFalda W, Kwong P, Eads K, McCafferty M, Rieger J, Glover DK, Willson C, Burnett P, Olivadoti M. Dermatol Ther (Heidelb). 2021 Oct;11(5):1623-1634. doi: 10.1007/s13555-021-00576-y. Epub 2021 Jul 21.

The Hidden Impact of Molluscum Contagiosum: A survey of caregivers’ experiences with diagnosis, treatment, and impact on quality of life. Kwong P, Hebert AA, Utley C, Olivadoti M. SKIN. 2021 Jul; 5 (4).

Safety and Efficacy of VP-102 (Cantharidin, 0.7% w/v) in Molluscum Contagiosum by Body Region: Post hoc Pooled Analyses from Two Phase III Randomized Trials. Eichenfield LF, Kwong P, Gonzalez ME, Yan A, D'Arnaud P, Burnett P, Olivadoti M. J Clin Aesthet Dermatol. 2021 Oct;14(10):42-47.

Phase II, Double-Blind, Vehicle-Controlled Study to Determine the Cantharidin Dose Regimen, Efficacy, Safety, and Tolerability of VP-102 in Subjects with External Genital Warts. Guenthner S, McFalda W, Tate M, Eads K, Rieger J, Glover DK, Willson C, Rumney P, Rosen T, Andres J, Olivadoti M. Am J Clin Dermatol. 2021 Nov;22(6):867-875. doi: 10.1007/s40257-021-00635-2. Epub 2021 Sep 13.

Improvement in disease severity and pruritus outcomes with crisaborole ointment, 2%, by baseline atopic dermatitis severity in children and adolescents with mild-to-moderate atopic dermatitis. Eichenfield LF, Yosipovitch G, Stein Gold LF, Kalabis M, Zang C, Vlahos B, Sanders P, Myers DE, Bushmakin AG, Cappelleri JC, Olivadoti M, Paller AS. Pediatr Dermatol. 2020 Nov;37(6):1030-1037. doi: 10.1111/pde.14328. Epub 2020 Sep 27.

Medical Writing Examples

AZR-MD-001 0.5% selenium sulfide ophthalmic ointment for the treatment of contact lens discomfort: A vehicle-controlled, randomized, clinical trial. Stapleton F, Hinds M, Tan J, Jones L, Chalmers R, Bosworth C, Alster Y. Ocul Surf. 2025 Oct;38:431-439. doi: 10.1016/j.jtos.2024.12.009. Epub 2024 Dec 28. PMID: 39736410.

Efficacy and safety of AZR-MD-001 selenium sulfide ophthalmic ointment in adults with meibomian gland dysfunction over six months of treatment: A Phase 2, vehicle-controlled, randomized extension trial. Downie LE, Craig JP, Stapleton F, Tan J, Jones LW, Ng A, Hinds M, Bosworth C, Alster Y. Ocul Surf. 2025 Jan;35:15-24. doi: 10.1016/j.jtos.2024.11.008. Epub 2024 Nov 28. PMID: 39613259.

Demodex blepharitis treatment with a selenium sulfide-containing ointment: a case report. Alster Y, Rafaeli O, Bosworth C. Ther Adv Ophthalmol. 2026 Jan 4;18:25158414251405397. doi: 10.1177/25158414251405397. PMID: 41509818; PMCID: PMC12775352.

Seminar Examples

B2B and Consumer Content Examples